Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Hospitals in the USA are overwhelmed with a surge in patients due to a 'quad-demic' of flu, Covid-19, RSV, and norovirus.

About 8 in 10 infants received respiratory syncytial virus protection during the 2023 to 2024 season, according to study findings.

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions ...

Moderna advances combo vaccine for flu and COVID-19 with trials starting in March Pharmaceutical companies gear up to tackle ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...